文献速递临床试验与 GCP基础与转化研究组学、生物样本库与精准医学

大柴胡汤治疗肥胖合并非酒精性脂肪性肝病:随机双盲安慰剂对照预试验方案

Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
PubMed 文献 · Trials · 2020-01-31

本文报告一项随机、双盲、平行组、分层、安慰剂对照预试验方案,拟招募60例BMI≥25 kg/m2的NAFLD患者,给予大柴胡汤或安慰剂3 g每日三次共12周并随访4周,以体重平均变化为主要指标,评估可行性并探索肠道菌群机制。

要点

  • 受试者为BMI≥25 kg/m2的NAFLD患者,共60例。
  • 干预为大柴胡汤或安慰剂3 g每日三次,共12周,随访4周。
  • 主要指标为体重平均变化,次要指标含体成分、肝脂肪定量及肠道菌群。

核心结论

  • 该预试验旨在为后续全尺度临床试验评估大柴胡汤用于肥胖伴NAFLD患者的可行性。

研究设计与样本

  • 研究为随机、双盲、平行组、分层、安慰剂对照预试验的方案。
  • 计划招募60例BMI≥25 kg/m2的NAFLD患者。
  • 干预为DST或安慰剂3 g每日三次共12周,另设4周随访期。

关键数值与推荐

  • 纳入标准为NAFLD且体重指数≥25 kg/m2。
  • 主要测量指标为体重平均变化。
  • 次要参数包括体成分、人体测量、血液检查、瞬时弹性成像肝脂肪定量及躯体症状问卷。
  • 干预前后采集粪便样本用于肠道微生物分析。

临床怎么用

  • 该方案尚处于预试验阶段,结果未报告,暂不能形成临床用药推荐。

局限性

  • 原文为研究方案,未报告实际结果数据。
  • 样本量为60例,属预试验规模。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The high prevalence of obesity and non-alcoholic fatty acid disease has become an important public health problem. Daesiho-tang (DST) is an herbal medicine widely used to treat obesity, metabolic syndrome and liver diseases. This pilot study will assess the feasibility of using DST in obese patients with a non-alcoholic fatty liver disease (NAFLD) prior to undertaking a full-scale clinical trial. METHODS/DESIGN: This is a study protocol for a randomised, double-blind, parallel-group, stratified, placebo-controlled pilot trial. We will recruit a total of 60 participants with NAFLD who have a body mass index ≥ 25 kg/m2. They will take either DST or placebo (3 g, three times daily) for 12 weeks with a 4-week follow-up period. The effects of DST will be evaluated by the mean change in body weight as the primary measurement and other secondary parameters (body composition, anthropometric measurements, blood tests, hepatic fat quantification through transient elastography and a physical symptoms questionnaire). Faecal samples will be collected before and after the intervention for a gut microbial analysis. DISCUSSION: In anticipation of conducting further large-scale trials, in this study we will explore the effect of DST on weight loss and obesity-related markers, along with NAFLD-related clinical parameters, in obese patients with NAFLD. Furthermore, it will provide insight into the DST pharmacological mechanism of action through a gut microbiome analysis. TRIAL REGISTRATION: Korean Clinical Trial Registry, KCT0003554. Registered on 25 February 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Han K, Kwon O, Park HJ, et al. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial. Trials. 2020. PMID: 32005283. doi:10.1186/s13063-020-4068-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。